[144] Acumen Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Acumen Pharmaceuticals, Inc. insider Matt Zuga filed a notice of proposed sale under Rule 144. The filing covers the planned sale of 2,473 shares of common stock through Merrill Lynch on or about January 21, 2026 on NASDAQ, with an indicated aggregate market value of $4,469.18. The shares came from the vesting of a restricted stock unit award on January 17, 2026 granted as part of the issuer’s equity compensation plan.

The notice also lists recent sales of Acumen common stock by Zuga over the past three months. These include separate sales of 4,000, 5,100, 5,805, and 6,888 shares on January 5–8, 2026, with gross proceeds of $7,842.33, $10,027.50, $11,565.85, and $12,513.07, respectively. By signing, the seller represents that he is not aware of undisclosed material adverse information about the company.

Insights

Equity capital markets analyst

Routine Rule 144 sale following equity award vesting; neutral impact.

This notice outlines a planned Rule 144 sale by Matt Zuga of 2,473 shares of Acumen Pharmaceuticals, Inc. common stock, to be sold via Merrill Lynch on or about January 21, 2026. The shares were acquired through the vesting of a restricted stock unit award on January 17, 2026 under the company’s equity compensation plan, which is a common mechanism for executive and insider compensation.

The filing also details several recent open-market sales from January 5–8, 2026, each with disclosed share counts and gross proceeds, indicating ongoing portfolio management rather than a single large transaction. The seller’s representation that he is not aware of undisclosed material adverse information is a standard Rule 144 requirement. Based on the information provided, this appears to be a routine insider sale with a neutral effect on the broader investment thesis.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	2473	4469.18	60573425	01/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	01/17/2026	Vesting of restricted stock unit award	Acumen Pharmaceuticals, Inc.			2473	01/17/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Matt Zuga 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/05/2026	4000	7842.33
Matt Zuga 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/06/2026	5100	10027.50
Matt Zuga 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/07/2026	5805	11565.85
Matt Zuga 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/08/2026	6888	12513.07

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)